Serum levels of soluble TNF-α receptors but not BDNF are associated with apathy symptoms in mild Alzheimer’s disease and amnestic mild cognitive impairment

Henrique Cerqueira Guimarães1, Paulo Caramelli1, Patricia Paes Araujo Fialho1, Elisa de Paula França1, Marcelo Pelizzaro Dias Afonso1, Antonio Lucio Teixeira1,2

ABSTRACT. Apathy is intimately associated with dementia. Unfortunately, its pathophysiology remains poorly understood. The motivational impairment that characterizes this disorder might share the same inflammatory mechanisms, as suggested by the sickness behavior theory. Objective: The primary aim of this study was to investigate the association between apathy symptoms and serum levels of tumor necrosis factor alpha (TNF-α) and its soluble receptors. Brain-derived neurotrophic factor (BDNF) levels were also analyzed since these have been associated with depression, a condition which shares abulic features with apathy. Methods: The sample consisted of 27 subjects with mild Alzheimer’s disease or amnestic mild cognitive impairment, who were submitted to specific apathy evaluation using the Apathy Scale (AS) and provided blood samples for biomarker analysis. Participants were categorized into two groups according to median AS scores (17 points). Results: Subjects with higher apathy symptoms (n=13) displayed higher levels of TNF-α soluble receptors (type 1: p=0.03; type 2: p=0.04). No other difference was found between groups. Conclusion: These findings point to the involvement of inflammatory mediators in the genesis of apathy symptoms, as suggested by the sickness behavior theory.

INTRODUCTION

Apathy is a pervasive feature in several neuropsychiatric disorders. Most of our current understanding regarding this behavioral syndrome was built upon research on neuro-
degenerative conditions. Generally speaking, apathy has been shown to be the most prevalent behavioral disorder in dementia. Once identified, apathetic symptoms follow a prolonged and mostly definitive course throughout cognitive decline, leading to a sharp increase in apathy prevalence and severity as dementia reaches its moderate to advanced stages.

There is fairly good agreement in the literature that apathy should be considered an independent syndrome in dementia, with specific clinical implications and probable worse outcomes. Another emerging consensus is that apathy can be recognized in a significant proportion of mild cognitive impairment (MCI) subjects, especially those regarded as amnestic. Longitudinal studies have suggested a substantially increased risk of dementia conversion in these MCI apathetic subjects. Unfortunately, scant therapeutic options are available to improve this devastating disorder, a fact which, at least partially, can be ascribed to a poor understanding of the neurobiological underpinnings of apathy.

Marin defined apathy as “lack of motivation, relative to the patient’s previous level of functioning or the standards of his or her age and culture, not attributable to intellectual impairment, emotional distress or diminished level of consciousness”. The motivational feature has remained the core diagnostic criteria in a consensus proposition to identify apathy in Alzheimer disease (AD) and other neuropsychiatric disorders. Lack of motivation is also the core feature of sickness behavior. This is a coordinated set of behavioral adaptations that also includes a neurovegetative dimension (fatigue, loss of appetite and sleep disorders), and a psychological dimension (depressed mood, anxiety and cognitive dysfunction), that are supposed to reorganize the organism’s priorities to cope with infectious pathogens. TNF-α, a proinflammatory cytokine, plays a pivotal role in triggering sickness behavior. The levels of this cytokine have also been shown to be increased in a sample of MCI and AD patients. Since inflammatory mechanisms play a putative role in the pathophysiology of several types of neurodegeneration, and apathy is a pervasive feature in dementia, it is reasonable to investigate whether these two phenomena are associated.

The primary aim with this study was to investigate whether blood TNF-α, and its soluble receptors, are associated with apathy symptoms. Soluble forms of TNF-α receptors represent reliable markers of this cytokine activity, binding to and protecting TNF-α from proteolytic degradation, therefore, extending its effects systemically. We also investigated the possible association between BDNF and apathy, since there has been a previous report of reduced levels of this neurotrophic factor in subjects with late-life depression, a condition that shares abulic features with apathy. To accomplish this objective we evaluated only subjects with cognitive impairment in its very early stages, namely mild AD and amnestic MCI (aMCI), since inflammatory status has been related to frailty, an almost inexorable outcome in moderate and advanced stages of late-onset dementia.

METHODS
Participants and procedures. This study was a retrospective analysis of the available clinical and laboratory data for a small subset of participants from the Pietà Study, a community-based survey of successful aging, carried out in Caeté, Southeast Brazil, in the summer of 2008.

A total of 639 subjects were submitted to a thorough functional, clinical, psychiatric and neurological evaluation, including the Functional Activities Questionnaire (FAQ), the motor section of the Unified Parkinson’s disease rating scale (UPDRSs), the Mini-Mental State Examination (MMSE), the CERAD (Consortium To Establish A Registry For AD) protocol, phonemic verbal fluency tasks (FAS), Frontal Assessment Battery, and the Dementia Rating Scale. A subset of 358 subjects provided blood samples for routine and inflammatory biomarker analyses.

Among the participants submitted to the above evaluation, two groups of subjects were identified and invited for further clinical assessment pertaining to apathy and behavioral evaluation. The first group of participants consisted of 28 subjects fulfilling NINCDS-ADRDA diagnostic criteria for probable Alzheimer disease in the mild stage of dementia. AD staging was accomplished through the Functional Assessment Staging...
in Alzheimer Disease (FAST). Only those categorized as FAST 4 or below were included. None of the AD subject were taking cholinesterase inhibitors at the time of evaluations. Vascular dementia was ruled out according to NINDS-AIREN criteria. The second group consisted of 26 subjects with aMCI, diagnosed according to Petersen’s criteria. Amnestic impairment was established by comparing performances on the Rey Auditory Verbal Learning Test (RAVLT) by cognitively healthy subjects from the same population. Subjects with a major depressive episode, diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders fourth edition, were excluded. Of the 52 subjects with either mild AD or amnestic MCI who were submitted to apathy and behavioral evaluation, 27 underwent blood analysis, giving the final study sample reported.

**Apathy and behavioral assessment.** Since there were no published consensual diagnostic criteria for apathy at the time of data collection, this disorder was evaluated dimensionally through the Apathy Scale (AS), which was administered to caregivers or to a very close member of the household. The AS has 14 questions with a score ranging from zero to 42 points, where higher scores represent more severe apathetic symptoms. Despite a lack of consensus regarding this issue, previous studies have suggested a cut-off of 14 points in order to identify clinically relevant apathy. Subjects were also submitted to the Neuropsychiatric Inventory (NPI).

**Laboratory assessment.** Blood was drawn during fasting and in the early morning for all the participants. Serum levels of BDNF, TNF-α, sTNF-R1, and sTNF-R2 were measured.

| Table 1. Comparison of higher vs lower apathy symptoms groups, according to demographics. |
|---------------------------------------------|------------------|------------------|------------------|------------------|
| **Apathy scale**                           | **Lower apathy symptoms (n=14)** | **Higher apathy symptoms (n=13)** | **p - value** |
| **%** | **mean** | **SD** | **%** | **mean** | **SD** | **%** | **mean** | **SD** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Age, years | 82.9 | 3.9 | 80.5 | 4.6 | 0.08 |
| Gender (male, %) | 28.6 | 61.5 | 3.6 | 3.8 | 2 | n.s. |
| Education, years | 62.9 | 28.1 | 15.9 | 4.5 | n.s. |
| Weight, Kg | 62.6 | 26.6 | 5.1 | 13.9 | n.s. |
| Body mass index | 26.6 | 35.7 | 5.1 | 61.5 | 6.2 | n.s. |
| Alzheimer’s disease (%) | 28.6 | 28.1 | 61.5 | 4.5 | n.s. |
| Cognitive and functional measures | 6.2 | 26.1 | 7.3 | 3.9 | <0.0001 |
| Functional Assessment Questionnaire | 20.3 | 6.1 | 4.4 | 6.2 | n.s. |
| Mini-Mental State Examination | 100.3 | 20.4 | 19.8 | 4.8 | n.s. |
| Dementia Rating Scale | 6.2 | 105.1 | 2.7 | 11.7 | n.s. |
| Frontal Assessment Battery | 6.2 | 6.7 | 2.7 | 2.3 | n.s. |
| Behavioral evaluation | 6.2 | 10.4 | 2.7 | 4.5 | <0.0001 |
| Apathy Scale | 0.0 | 0.0 | 0.0 | 3.3 | 0.003 |
| NPI - apathy | 7.3 | 10.3 | 14.8 | 9.8 | 0.06 |
| NPI - total | 4.0 | 4.0 | 2.1 | 3.4 | n.s. |
| Geriatric Depression Scale | 1418.3 | 273.9 | 353.9 | 86.3 | 0.10 |
| Biomarkers | 227.9 | 291.6 | 546.8 | 93.8 | n.s. |
| BDNF (pg/ml) | 273.9 | 291.6 | 86.3 | 93.8 | 0.03 |
| TNF-α (pg/ml) | 360.5 | 377.2 | 111.9 | 138.6 | n.s. |
| sTNF-R type1 (pg/ml) | 1668.9 | 227.9 | 398.6 | 546.8 | 0.04 |
| **NPI:** Neuropsychiatric inventory; **UPDRS:** Unified Parkinson’s disease rating scale - motor section; **BDNF:** brain-derived neurotrophic factor; **TNF:** Tumor necrosis factor; **sTNF -R:** TNF soluble receptors; **n.s.:** non-significant; *Chi-square test.
measured according to the procedures supplied by the manufacturer, and using ELISA kits for TNF-α (Quantikine, R&D Systems, Minneapolis, MN, USA), soluble TNF-α receptors and BDNF (DuoSet, R&D Systems, Minneapolis, MN, USA). All samples were assayed in duplicate, yielding concentrations expressed as pg/ml. The detection limits were 0.1 pg/ml for TNF-α, 10 pg/ml for both soluble receptors, and 5 pg/ml for BDNF.

**Statistical analysis.** An exploratory analysis with the D’Agostino-Pearson test showed that most of the data had non-normal distributions. The 27 eligible subjects were split into two groups according to median AS scores (17 points), forming one group with higher (AS >17) and another with lower apathy symptoms (AS ≤17). Differences between groups were investigated using the Mann-Whitney test for continuous variables and Chi-square test for categorical data. Correlation analysis was performed using Spearman’s rho coefficient. Statistical significance was set as a p-value ≤0.05.

**RESULTS**

The target sample consisted of 27 subjects (15 women, 12 men), with a mean age of 81.5±4.6 years, and 3.2±2.7 mean years of formal education. According to cognitive status, 14 subjects presented mild AD and 13 had aMCI. The median score on the AS was 17 points, providing two groups with different intensity of apathy symptoms.

Table 1 displays the comparison between the groups, regarding demographics, anthropometrics, cognitive status; cognitive, motor, functional and behavioral measures, and, lastly, BDNF and inflammatory biomarker levels. As expected, apathy measures differed between the groups. The higher apathy symptoms group had higher levels of both types of TNF-α soluble receptors (sTNF-R1: p=0.03; sTNF-R2: p=0.04). These results are illustrated in Figure 1. Soluble TNF-α receptors levels also correlated with AS scores (sTNF-R1: rho=0.49; p=0.01; sTNF-R2: rho=0.40; p=0.037), considering the whole sample. BDNF and TNF-α levels did not differ significantly between groups. No other variables reached statistical significance, except for age and NPI-total scores which displayed a tendency towards significance. Nevertheless, NPI-total scores did not correlate with levels of any of the TNF-α soluble receptor types (sTNF-R1: rho=0.05, p=0.82; sTNF-R2: rho=0.22, p=0.29). Additionally, although there was a marked difference between groups regarding proportions of gender and AD subjects, levels of TNF-α soluble receptors were not different in pairwise comparison (Mann-Whitney test), either between genders (sTNF-R1: p=0.09; sTNF-R2: p=0.3) or between different cognitive status groups (sTNF-R1: p=0.7; sTNF-R2: p=0.29), suggesting that these variables were not driving the results.

**DISCUSSION**

In this retrospective investigation of a small subset of subjects from the Pietà study involving participants who had provided a blood sample for inflammatory biomarker analysis and were also submitted to apathy evaluation, we found elevated levels of both soluble TNF-α receptors in subjects with greater apathy symptoms. The negative results found for TNF-α levels are unsurprising. This cytokine has a very short half-life and remains below the assay threshold in a significant proportion of subjects. As stated earlier, soluble receptors constitute more reliable markers of blood TNF-α signaling. To the best of our knowledge, this is the first...
study that has used a specific apathy scale to investigate association of the condition with TNF-α and its soluble receptors. A previous report found an association between GDS items, assumed to mirror apathy, and higher TNF-α levels in male patients with AD.28 The findings herein reported are in accordance with the sickness behavior motivational impairment theory, and might constitute a reasonable explanation for apathy ubiquity and its worsening in progressive neurodegenerative disorders. Surprisingly, very few studies have explored this association. A previous report found no relationship between a GDS surrogate apathy measure and C-reactive protein (CRP) levels.29 However, this acute phase reaction protein may not be the most suitable inflammatory biomarker to investigate this issue, since apathy and cognitive impairment are supposed to result from a chronic phenomenon. In line with the theoretical framework underlying this report, Ferretti et al reported, for a cohort of schizophrenic patients, a significant improvement in negative symptoms, including apathy, by treating them with minocycline, 30 a drug with putative anti-inflammatory properties. 31

None of the other investigated variables were found to be associated with AS scores. The two groups displayed similar depression scores, and also had similar mean performances on motor, global cognitive and executive function measures. The apparent difference regarding gender and dementia proportions between groups did not reach statistical significance, and these features were not associated with soluble TNF-α receptors. Although there was a clinically significant difference between higher and lower apathy symptoms groups regarding mean performance on the FAQ, corroborating results of a previous report, 32 these findings did not reach statistical significance. It is important to note that BDNF levels were higher in the more apathetic group, in contrast to previous findings from a late-life depression cohort. 33 This finding adds to a large body of evidence regarding clinical and neuroimaging data that dissociates apathy from depression.2

The small sample size can be considered a serious limitation of our study. Additionally, this is an emerging research field, precluding a robust hypothesis that might explain the neuroimmunology of these findings. Another important point is that the concept of MCI has proven to be, in recent years, a highly heterogeneous condition. 33 Thus, it is reasonable to question the validity of pooling clinically defined AD and MCI groups together. However, as stated previously, inflammatory mechanisms seem to play a fundamental role in several neurodegenerative diseases, independently of their etiology, constituting a pervasive feature of dementia, akin to apathy. Lastly, the findings herein reported are preliminary and should be replicated in larger samples.

Acknowledgements. The study was supported by CNPq, FAPEMIG, Instituto Hermes Pardini, and Laboratório Geraldo Lustosa.

REFERENCES

1. van Reekum R, Stuss DT, Ostrander L. Apathy: why care? J Neuropsychiatry Clin Neurosci 2005;17:7-19.
2. Guimarães HC, Levy R, Teixeira AL, Beato RG, Caramelli P. Neurobiology of apathy in Alzheimer’s disease. Arq Neuropsiquiatr 2008;66:436-443.
3. Robert P, Onyike CU, Leentjens AF, et al. Proposed diagnostic criteria for apathy in Alzheimer’s disease and other neuropsychiatric disorders. Eur Psychiatry 2009;24:98-104.
4. Craig D, Mirakhor A, Hart DJ, McIlroy SP, Passmore AP. A cross-sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer’s disease. Am J Geriatr Psychiatry 2005;13:460-468.
5. Starkstein SE, Petracca G, Chemerinski E, Kremer J. Syndromic validity of apathy in Alzheimer’s disease. Am J Psychiatry 2001;158:872-877.
6. Starkstein SE, Jorge R, Mizrahi R, et al. A prospective longitudinal study of apathy in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2006;77:10-17.
7. Robert PH, Ber C, Volta M, et al. Neuropsychological performance in mild cognitive impairment with and without apathy. Dement Geriatr Cogn Disord 2006;21:192-197.
8. Geda YE, Roberts RO, Knopman DS, et al. Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: a population-based study. Arch Gen Psychiatry 2008;65:1193-1198.
9. Robert PH, Ber C, Volta M, et al. Apathy in patients with mild cognitive impairment and the risk of developing dementia of Alzheimer’s disease: a one-year follow-up study. CIn Neurol Neurosurg 2006;108:733-736.
10. Marin RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci 1991;3:243-254.
11. Dantzer R. Cytokine-induced sickness behavior: mechanisms and implications. Ann N Y Acad Sci 2001;933:22-34.
12. Palin K, Bluthe RM, McClusker RH, et al. The type 1 TNF receptor and its associated adapter, FAN, are required to TNF-α induced sickness behavior. Psychopharmacology 2009;201:549-56.
13. Bermejo P, Martín-Aragón S, Benedí J, et al. Differences in peripheral inflammatory markers between mild cognitive impairment and Alzheimer’s disease. Immunol Lett 2008;117:198-202.
14. Amor S, Puentes F, Baker D, van der Valk P. Inflammation in neurodegenerative diseases. Immunology 2010;129:154-169.
15. Wajant H, Pitzenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003;10:46-65.
16. Diniz BS, Teixeira AL, Talib LL, Mendonça VA, Gattaz WF, Forlenza OV. Serum brain-derived neurotrophic factor level is reduced in antidepressant-free patients with late-life depression. World J Biol Psychiatry 2010;11:550-565.
17. Hubbard RE, O’Mahony MS, Sawa GM, Calver BL, Woodhouse KW. Inflammation and frailty measures in older people. J Cell Mol Med 2009;13:3103-3109.
18. Coelho FM, Narciso FM, Oliveira DM, et al. sTNFR-1 is an early inflammatory marker in community versus institutionalized elderly women. Inflamm Res 2010;59:129-134.
19. Caramelli P, Barbosa MT, Sakurai E, et al. The Pietà Study: epidemiological investigation in successful brain aging in Caecl(MG), Brazil. Methods and baseline cohort characteristics. Arq Neuropsiquiatr 2011;69:579-584.
Guimarães HC, et al.  

TNF-α and apathy in Alzheimer’s disease

21. Reisberg B. Functional assessment staging (FAST). Psychopharmacol Bull 1988;24:653-659.

22. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-259.

23. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183-194.

24. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM). 4th ed. Washington, DC: American Psychiatric Association, 1994.

25. Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG. Reliability, validity and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1992;4:134-139.

26. Funkiewiez A, Bertoux M, de Souza LC, Levy R, Dubois B. The SEA (Social Cognition and Emotional Assessment): A clinical neuropsychological tool for early diagnosis of frontal variant frontotemporal lobar degeneration. Neuropsychology 2012;26:81-90.

27. Cummings JL, Mena M, Gray K, Rosenberg-Thompson S, Carusi DA, Gurney J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2313.

28. Hall JR, Vo HT, Johnson LA, Winer S, Barner RC, O’Byrnan SE. Biomarkers and depressive symptoms in a sample of cognitively intact and Alzheimer’s disease elderly males. Neuroscience Med 2011;2:306-312.

29. Maas DW, van der Mast RC, de Craen AJ. Increased C-reactive protein is not associated with apathy: the Leiden 85-Plus Study. Int J Geriatr Psychiatry 2009;24:1177-1184.

30. Chaudhry IB, Hallak J, Husain N, et al. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol 2012;26:1185-93.

31. Ferretti MT, Allard S, Partridge V, Ducatenzeiler A, Cuello AC. Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer’s disease-like amyloid pathology. J Neuroinflammation 2012;9:62.

32. Boyle PA, Malloy PF, Salloway S, Cahn-Weiner DA, Cummings JL. Executive dysfunction and apathy predict functional impairment in Alzheimer disease. Am J Geriatr Psychiatry 2003;11:214-221.

33. Petersen RC, Aisen P, Boeve BF, et al. The NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology 1984;34:939-944.

34. Guimarães HC, et al.  

TNF-α and apathy in Alzheimer’s disease

21. Reisberg B. Functional assessment staging (FAST). Psychopharmacol Bull 1988;24:653-659.

22. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-259.

23. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183-194.

24. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM). 4th ed. Washington, DC: American Psychiatric Association, 1994.

25. Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG. Reliability, validity and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1992;4:134-139.

26. Funkiewiez A, Bertoux M, de Souza LC, Levy R, Dubois B. The SEA (Social Cognition and Emotional Assessment): A clinical neuropsychological tool for early diagnosis of frontal variant frontotemporal lobar degeneration. Neuropsychology 2012;26:81-90.

27. Cummings JL, Mena M, Gray K, Rosenberg-Thompson S, Carusi DA, Gurney J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2313.

28. Hall JR, Vo HT, Johnson LA, Winer S, Barner RC, O’Byrnan SE. Biomarkers and depressive symptoms in a sample of cognitively intact and Alzheimer’s disease elderly males. Neuroscience Med 2011;2:306-312.

29. Maas DW, van der Mast RC, de Craen AJ. Increased C-reactive protein is not associated with apathy: the Leiden 85-Plus Study. Int J Geriatr Psychiatry 2009;24:1177-1184.

30. Chaudhry IB, Hallak J, Husain N, et al. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol 2012;26:1185-93.

31. Ferretti MT, Allard S, Partridge V, Ducatenzeiler A, Cuello AC. Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer’s disease-like amyloid pathology. J Neuroinflammation 2012;9:62.

32. Boyle PA, Malloy PF, Salloway S, Cahn-Weiner DA, Cummings JL. Executive dysfunction and apathy predict functional impairment in Alzheimer disease. Am J Geriatr Psychiatry 2003;11:214-221.

33. Petersen RC, Aisen P, Boeve BF, et al. Criteria for mild cognitive impairment due to Alzheimer’s disease in the community. Ann Neurol. 2013[Epub ahead of print].